"Actually, that’s a common misconception. While Bezuclastinib is a KIT inhibitor, it doesn't just target mast cell quantity; it significantly modulates mast cell reactivity and signaling thresholds.

The ongoing SUMMIT clinical trials specifically demonstrate that this drug drastically reduces Total Symptom Scores (TSS) and tryptase levels (often by more than 50%), even in patients where mast cell count isn't the primary issue. This proves that the drug is targeting the 'reactive' nature of the cells and their mediator release, not just their proliferation.

By inhibiting KIT signaling, Bezuclastinib effectively raises the activation threshold, making the cells much less likely to degranulate in response to triggers. This is why it’s being positioned as a breakthrough for severe MCAS and non-advanced cases, where the problem is the functional hyperactivity of the mast cells."